Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832575 | 0.91 | DRD1 (0.33) | ALDH1A1TSHRNPBWR1MCHR1 | |
| SCHEMBL30939587 | 0.89 | MAPT (0.32) | MAPTALDH1A1TP53TSHRSLC6A2 | |
| SCHEMBL1979286 | 0.89 | MAPT (0.32) | MAPTALDH1A1TP53TSHRSLC6A2 | |
| SCHEMBL1978283 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TSHRKDM4ENPBWR1MCHR1 | |
| SCHEMBL30939633 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TSHRKDM4ENPBWR1MCHR1 | |
| SCHEMBL30939590 | 0.78 | NPSR1 (0.38) | MAPTALDH1A1TP53TSHRKDM4E | |
| SCHEMBL1979317 | 0.78 | NPSR1 (0.38) | MAPTALDH1A1TP53TSHRKDM4E | |
| SCHEMBL1979866 | 0.77 | AR (0.35) | MAPT | |
| SCHEMBL18963091 | 0.77 | AR (0.31) | MAPT | |
| SCHEMBL30939519 | 0.77 | AR (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MAPT 3789/4885ALDH1A1 462/4885TP53 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.